{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:14:41Z","timestamp":1789755281650,"version":"4.0.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"Objectives<\/jats:title>Daratumumab, a monoclonal antibody against CD38, is increasingly used in the treatment of multiple myeloma, other hematological malignancies and autoimmune diseases. Little is known about its CNS toxicity. We present a case of a patient with POEMS syndrome (syndrome of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) who developed an acute leukoencephalopathy shortly after initiation of therapy with daratumumab.<\/jats:p><\/jats:sec>Methods<\/jats:title>Case report following the CARE case report guidelines<\/jats:p><\/jats:sec>Results<\/jats:title>The patient presented with symptoms of headache and diffuse worsening of a pre-existing tetraparesis. MRI showed a rapidly progressive leukoencephalopathy. Extensive diagnostic evaluation revealed no specific cause, suggesting the leukoencephalopathy to be caused by daratumumab.<\/jats:p><\/jats:sec>Discussion<\/jats:title>Our report highlights a probably rare, but clinically significant adverse effect of daratumumab and underlines the necessity of raised vigilance for neurological side effects in patients treated with daratumumab.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1451693","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:25:20Z","timestamp":1727324720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute leukoencephalopathy associated with daratumumab treatment in POEMS syndrome: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Lukas","family":"Steinegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Nierobisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Vere-Tyndall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Kana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Herwerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.03.010","article-title":"Evolving role of daratumumab: from backbencher to frontline agent","volume":"20","author":"Jain","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23139","article-title":"CD38 positively regulates postnatal development of astrocytes cell-autonomously and oligodendrocytes non-cell-autonomously","volume":"65","author":"Hattori","year":"2017","journal-title":"Glia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0006-8993(97)00117-0","article-title":"Ultrastructural localization of CD38 immunoreactivity in rat brain","volume":"756","author":"Yamada","year":"1997","journal-title":"Brain Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: Update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-023-00859-x","article-title":"Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience","volume":"13","author":"Vaxman","year":"2023","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S365657","article-title":"Leukoencephalopathy during daratumumab-based therapy: A case series of two patients with multiple myeloma","volume":"15","author":"Kareem","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05120-w","article-title":"Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma","volume":"102","author":"Liu","year":"2023","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0321","article-title":"A rare case of daratumumab-associated encephalopathy in multiple myeloma","volume":"16","author":"Xiang","year":"2024","journal-title":"Immunotherapy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.229","article-title":"The daratumumab crosses the blood brain barrier","volume":"18","author":"Vercruyssen","year":"2018","journal-title":"Cl Lymph Myelom Leuk"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09233-z","article-title":"Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome","volume":"266","author":"Ziff","year":"2019","journal-title":"J Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bd136b","article-title":"Cerebral infarction in POEMS syndrome Incidence, risk factors, and imaging characteristics","volume":"73","author":"Dupont","year":"2009","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i51","article-title":"Ischemic stroke in patients with POEMS syndrome: a case report and comprehensive analysis of literature","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2214\/AJR.08.1176","article-title":"Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging","volume":"193","author":"McKinney","year":"2009","journal-title":"AJR Am J Roentgenol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1451693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:25:21Z","timestamp":1727324721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1451693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2024.1451693"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1451693","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"article-number":"1451693"}}